Literature DB >> 21117621

Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.

Malou Henriksen-Lacey1, Dennis Christensen, Vincent W Bramwell, Thomas Lindenstrøm, Else Marie Agger, Peter Andersen, Yvonne Perrie.   

Abstract

The immunostimulatory capacities of cationic liposomes are well-documented and are attributed both to inherent immunogenicity of the cationic lipid and more physical capacities such as the formation of antigen depots and antigen delivery. Very few studies have however been conducted comparing the immunostimulatory capacities of different cationic lipids. In the present study we therefore chose to investigate three of the most well-known cationic liposome-forming lipids as potential adjuvants for protein subunit vaccines. The ability of 3β-[N-(N',N'-dimethylaminoethane)carbomyl] cholesterol (DC-Chol), 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), and dimethyldioctadecylammonium (DDA) liposomes incorporating immunomodulating trehalose dibehenate (TDB) to form an antigen depot at the site of injection (SOI) and to induce immunological recall responses against coadministered tuberculosis vaccine antigen Ag85B-ESAT-6 are reported. Furthermore, physical characterization of the liposomes is presented. Our results suggest that liposome composition plays an important role in vaccine retention at the SOI and the ability to enable the immune system to induce a vaccine specific recall response. While all three cationic liposomes facilitated increased antigen presentation by antigen presenting cells, the monocyte infiltration to the SOI and the production of IFN-γ upon antigen recall was markedly higher for DDA and DC-Chol based liposomes which exhibited a longer retention profile at the SOI. A long-term retention and slow release of liposome and vaccine antigen from the injection site hence appears to favor a stronger Th1 immune response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21117621     DOI: 10.1021/mp100208f

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  34 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.

Authors:  Roma Sinha; Jayeeta Roychoudhury; Partha Palit; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

Review 3.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

4.  Specific T cell induction using iron oxide based nanoparticles as subunit vaccine adjuvant.

Authors:  Lázaro Moreira Marques Neto; Nicholas Zufelato; Ailton Antônio de Sousa-Júnior; Monalisa Martins Trentini; Adeliane Castro da Costa; Andris Figueiroa Bakuzis; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

Review 5.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

6.  A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle.

Authors:  Yun Hu; Hong Zheng; Wei Huang; Chenming Zhang
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

Review 7.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

8.  Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.

Authors:  Jasdave S Chahal; Omar F Khan; Christopher L Cooper; Justine S McPartlan; Jonathan K Tsosie; Lucas D Tilley; Saima M Sidik; Sebastian Lourido; Robert Langer; Sina Bavari; Hidde L Ploegh; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-05       Impact factor: 11.205

9.  Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hspx, PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate.

Authors:  Davood Mansury; Kiarash Ghazvini; Saeid Amel Jamehdar; Ali Badiee; Mohsen Tafaghodi; Amin Reza Nikpoor; Yousef Amini; Mahmoud Reza Jaafari
Journal:  Rep Biochem Mol Biol       Date:  2019-01

Review 10.  Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review.

Authors:  Ehsan Raoufi; Bahar Bahramimeimandi; M Salehi-Shadkami; Patcharida Chaosri; M R Mozafari
Journal:  Biomedicines       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.